Multidrug-resistant and extensively drug-resistant tuberculosis: A review of current concepts and future challenges

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 14, Issue 3, 2014, Pages 279-285

  Günther, Gunar ^a,b  

^a RESEARCH CENTER BORSTEL   (Germany)

^b UNIVERSITY OF NAMIBIA   (Namibia)

Author keywords

Antituberculosis drugs; Drug resistant; Resistance testing; Tuberculosis; Tuberculosis control

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CLAVULANIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; TERIZIDONE;

DISEASE CONTROL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS (TOPIC); MIXED INFECTION; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT COURSE THERAPY; SYSTEMATIC REVIEW (TOPIC); URINALYSIS;

ANTI-TUBERCULOSIS DRUGS; DRUG-RESISTANT; RESISTANCE TESTING; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ADULT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS;

EID: 84902208513     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.14-3-279     Document Type: Review

References (56)

1. World Health Organization. Global Tuberculosis Report. Geneva: WHO, 2013.
2. Skrahina A, Hurevich H, Zalutskaya A et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull WHO 2013;91:36-45.
3. World Health Organization. European Center of Disease Control: Tuberculosis surveillance and monitoring in Europe. Geneva: WHO, 2013.
4. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012;54:579-81.
5. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues CS. Nomenclature of drug-resistant tuberculosis. Lancet Infect Dis 2013;13:917.
6. Falzon D, Gandhi N, Migliori GB et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013;42:156-68.
7. National Tuberculosis Institute. Tuberculosis in a rural population of South India: a five-year epidemiological study. Bull WHO 1974;51:473-88.
8. Zhao Y, Xu S, Wang L et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012;366:2161-70.
9. Chiang CY, Van Deun A, Enarson DA. A poor drug-resistant tuberculosis programme is worse than no programme: time for a change. Int J Tuberc Lung Dis 2013;17:714-8.
10. Grzybowski S, Enarson D. Results in pulmonary tuberculosis patients under various treatment program conditions. Bull Int Union Tuberc 1978;53:70-5. (Pubitemid 9240283)
11. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF System. Geneva; WHO, 2011.
12. Steingart KR, Sohn H, Schiller I et al. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013;1:CD009593.
13. Boehme CC, Nicol MP, Nabeta P et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011;377:1495-505.
14. Van Rie A, Mellet K, John MA et al. False-positive rifampicin resistance on Xpert(R) MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis 2012;16:206-8.
15. Dheda K, Ruhwald M, Theron G et al. Point-of-care diagnosis of tuberculosis: past, present and future. Respirology 2013;18:217-32.
16. Crudu V, Stratan E, Romancenco E et al. First evaluation of an improved assay for molecular genetic detection of tuberculosis as well as rifampin and isoniazid resistances. J Clin Microbiol 2012;50:1264-9.
17. Miotto P, Cabibbe AM, Mantegani P et al. GenoType MTBDRsl performance on clinical samples with diverse genetic background. Eur Respir J 2012;40:690-8.
18. Lange C, Abubakar I, Alffenaar JW et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014. doi: 10.1183/09031936.00188313 [Epub ahead of print].
19. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012;12:201-9.
20. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. Geneva: WHO, 2011. http://whqlibdoc.who.int/publications/2011/9789241501583-eng.pdf [Accessed 13 May 2014].
21. Ahuja SD, Ashkin D, Avendano M et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLOS Med 2012;9:e1001300.
22. Van Deun A, Kya Jai Maug A, Halim MA et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-92.
23. Johnson JL, Hadad DJ, Boom WH et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:605-12. (Pubitemid 43845020)
24. Jacobson KR, Tierney DB, Jeon CY et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010;51:6-14.
25. World Health Organization. The use of short course regimen for drug resistant tuberculosis. Geneva: WHO, 2012.
26. Dalton T, Cegielski P, Akksilp S et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012;380:1406-17.
27. Brigden G, Nyang'wa BT, du Cros P et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull WHO 2014;92:68-74.
28. Working Group on New TB Drugs, 2014. www.newtbdrugs.org/pipeline- discovery.php [Accessed 28 March 2014].
29. Diacon AH, Donald PR, Pym A et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012;56:3271-6.
30. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-405.
31. Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60.
32. World Health Organization. The use of bedaquiline for the treatment of drug resistant tuberculosis. Geneva: WHO, 2013.
33. Yew WW, Nuermberger E. High-dose fluoroquinolones in short-course regimens for treatment of MDR-TB: the way forward? Int J Tuberc Lung Dis 2013;17:853-4.
34. Lee M, Lee J, Carroll MW et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-18.
35. Sotgiu G, Centis R, D'Ambrosio L et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012;40:1430-42.
36. Marrone MT, Venkataramanan V, Goodman M et al. Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2013;17:6-16.
37. Srivastava S, Peloquin CA, Sotgiu G, Migliori GB. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013;42:1449-53.
38. Vu DH, Bolhuis MS, Koster RA et al. Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2012;56:5758-63.
39. Ettehad D, Schaaf HS, Seddon JA et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Inf Dis 2012;12:449-56.
40. The Sentinel Project for Paediatric Drug-Resistant Tuberculosis. Management of drug resistant tuberculosis in children. A field guide. Boston; The Sentinel Project for Paediatric Drug-Resistant Tuberculosis, 2012.
41. Seddon JA, Furin JJ, Gale M et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012;186:953-64.
42. International Union against Tuberculosis and Lung Disease, Medicines sans Frontieres. Tuberculosis drugs under the microscope, 3rd ed. Geneva: International Union against Tuberculosis and Lung Disease; Medicines sans Frontieres, 2013.
43. Seddon JA, Hesseling AC, Finlayson H et al. Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study. Clin Infect Dis 2013;57:1676-84.
44. Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80. (Pubitemid 44780738)
45. Chamie G, Luetkemeyer A, Walusimbi-Nanteza M et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis 2010;14:1295-302.
46. Karim Abdool SS, Naidoo K, Grobler A et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011;365:1492-501.
47. Havlir DV, Kendall MA, Ive P et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011;365:1482-91.
48. Blanc FX, Sok T, Laureillard D et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365:1471-81.
49. Chiang CY, Van Weezenbeek C, Mori T, Enarson DA. Challenges to the global control of tuberculosis. Respirology 2013;18:596-604.
50. Diel R, Vandeputte J, de Vries G et al. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014;43:554-65.
51. Ayles H, Muyoyeta M, Du Toit E et al. Effect of household and community interventions on the burden of tuberculosis in southern Africa: the ZAMSTAR community-randomised trial. Lancet 2013;382:1183-94.
52. Churchyard GJ, Fielding KL, Lewis JJ et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med 2014;370:301-10.
53. Suthar AB, Lawn SD, del Amo J et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLOS Med 2012;9:e1001270.
54. Isaakidis P, Cox HS, Varghese B et al. Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLOS ONE 2011;6:e28066.
55. European Center of Disease Preventation and Control. Management of contacts of MDR TB and XDR TB patients. Stockholm: ECDC, 2012.
56. De Lorenzo S, Alffenaar JW, Sotgiu G et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013;41:1386-92.